Document is current
Any future updates will be listed below
-
Authors
Mandrioli, Jessica https://orcid.org/0000-0002-9244-9782
D’Amico, Roberto
Zucchi, Elisabetta
De Biasi, Sara
Banchelli, Federico
Martinelli, Ilaria
Simonini, Cecilia
Lo Tartaro, Domenico
Vicini, Roberto https://orcid.org/0000-0002-1799-6567
Fini, Nicola
Gianferrari, Giulia https://orcid.org/0000-0002-4260-0915
Pinti, Marcello
Lunetta, Christian
Gerardi, Francesca
Tarlarini, Claudia
Mazzini, Letizia
De Marchi, Fabiola https://orcid.org/0000-0003-0197-1880
Scognamiglio, Ada
Sorarù, Gianni
Fortuna, Andrea
Lauria, Giuseppe
Bella, Eleonora Dalla
Caponnetto, Claudia
Meo, Giuseppe
Chio, Adriano
Calvo, Andrea https://orcid.org/0000-0002-5122-7243
Cossarizza, Andrea https://orcid.org/0000-0002-5381-1558
-
Funding
Funding for this research was provided by:
Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica (RAP-ALS FGCR02/2015)
Pfizer (Wi211892)
- License Information
-
More Information
Article History
Received: 2 March 2023
Accepted: 31 July 2023
First Online: 17 August 2023
Competing interests
: J.M. reports receiving advisory board fees from Biogen, Amylix and Italfarmaco, grant support from Roche, and grant support from Pfizer (active study drug for this study by grant number Wi211892 to J.M.). ACh received consulting fees from Biogen, Cytokinetics, Amylyx. ACa reports receiving advisory board fees from Biogen and Amylix, and grant support from Cytokinetics. GL reports scientific advisory for CSL Behring, Biogen Inc, Vertex Pharmaceuticals Incorporated, Chromocell Corporation, Janssen Pharmaceuticals, Inc, Lilly, and the Bracco Group. C.L. has served as a scientific consultant for Mitsubishi Tanabe Pharma Europe, Cytokinetics, Neuraltus, and Italfarmaco. R.D.A., E.Z., S.D.B., F.B., I.M., C.S., D.L.T., R.V., N.F., G.G., M.P., F.G., C.T., L.M., F.D.M., A.S., G.S., A.F., E.D.B., C.C., G.M., A.Co. declare no competing interests. Disclosure forms provided by the authors are available with the full text of this article.
